These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30233142)

  • 41. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
    Bozdağ S; Gümüş K; Gümüş O; Unlü N
    Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis.
    Kimonis VE; Troendle J; Rose SR; Yang ML; Markello TC; Gahl WA
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3257-61. PubMed ID: 7593434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
    Smolin LA; Clark KF; Thoene JG; Gahl WA; Schneider JA
    Pediatr Res; 1988 Jun; 23(6):616-20. PubMed ID: 3393396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cysteamine therapy for children with nephropathic cystinosis.
    Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
    N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of food vehicles on in vitro performance of pantoprazole sodium delayed release sprinkle formulation.
    Wu KW; Zheng K; Tian L; Xia L; Hwang SY; Nwakama PE; Sun WJ; Kim MJ; Tampal N; Xu X; Boyce H; Feng X
    Int J Pharm; 2023 Mar; 635():122737. PubMed ID: 36801362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease.
    Guha S; Konkwo C; Lavorato M; Mathew ND; Peng M; Ostrovsky J; Kwon YJ; Polyak E; Lightfoot R; Seiler C; Xiao R; Bennett M; Zhang Z; Nakamaru-Ogiso E; Falk MJ
    Hum Mol Genet; 2019 Jun; 28(11):1837-1852. PubMed ID: 30668749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of cysteamine therapy in nephropathic cystinosis.
    Yudkoff M; Foreman JW; Segal S
    N Engl J Med; 1981 Jan; 304(3):141-5. PubMed ID: 7442733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A dissolution test for a pressure-controlled colon delivery capsule: rotating beads method.
    Yoshikawa Y; Hu Z; Kimura G; Murakami M; Yoshikawa H; Takada K
    J Pharm Pharmacol; 1999 Sep; 51(9):979-89. PubMed ID: 10528979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A potential new prodrug for the treatment of cystinosis: design, synthesis and in-vitro evaluation.
    McCaughan B; Kay G; Knott RM; Cairns D
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1716-9. PubMed ID: 18249536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicted reciprocal serum creatinine at age 10 years as a measure of renal function in children with nephropathic cystinosis treated with oral cysteamine.
    Gahl WA; Schneider JA; Schulman JD; Thoene JG; Reed GF
    Pediatr Nephrol; 1990 Mar; 4(2):129-35. PubMed ID: 2397178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous cysteamine therapy for nephropathic cystinosis.
    Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
    Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse reactions to oral cysteamine use in nephropathic cystinosis.
    Corden BJ; Schulman JD; Schneider JA; Thoene JG
    Dev Pharmacol Ther; 1981; 3(1):25-30. PubMed ID: 7307866
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis.
    Kaiser-Kupfer MI; Fujikawa L; Kuwabara T; Jain S; Gahl WA
    N Engl J Med; 1987 Mar; 316(13):775-9. PubMed ID: 3821824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis.
    Devereux G; Steele S; Griffiths K; Devlin E; Fraser-Pitt D; Cotton S; Norrie J; Chrystyn H; O'Neil D
    Clin Drug Investig; 2016 Aug; 36(8):605-12. PubMed ID: 27153825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of cysteamine on the upper gastrointestinal tract of children with cystinosis.
    Wenner WJ; Murphy JL
    Pediatr Nephrol; 1997 Oct; 11(5):600-3. PubMed ID: 9323287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early oral cysteamine therapy for nephropathic cystinosis.
    Gahl WA
    Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
    Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
    Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.